A Phase II Study of GC101 in NSCLC
28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.
Trial Details
- NCT ID
- NCT07560111
- Phase
- PHASE2
- Sponsor
- Shanghai Juncell Therapeutics
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Autologous Tumor Infiltrating Lymphocytes
- Locations (sample)
- Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
- 1\. Signed the informed consent form (ICF) and able to comply with the visits and related procedures specified in the protocol;
- 2\. Aged ≥18 years and ≤70 years, regardless of gender;
- Patients with non-small cell lung cancer who have been confirmed negative for EGFR mutations, ALK, and ROS-1 by prior genetic testing, meeting one …
- 4\. TILs can be isolated from a surgically resectable tumor region: the tissue volume must be \>150mm3, and the lesion has not received local treat…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →